LUGANO failure wipes billions from EyePoint valuation as LUCIA becomes decisive

EyePoint, Inc. has suffered a dramatic reassessment of its lead retinal franchise after DURAVYU failed the prespecified primary endpoint in the first of two pivotal Phase 3 wet age-related macular degeneration trials, sending the company’s shares down nearly 70% during August 17 trading. LUGANO did produce several commercially attractive results, including a 42% reduction in treatment burden, strong anatomical disease control and more than half of DURAVYU-treated patients remaining free of supplemental aflibercept through week 56. Those benefits were not enough to overcome failure on the trial’s primary comparison of best corrected visual acuity in the full randomized population, particularly because the favorable analysis cited by EyePoint, Inc. required the post-hoc exclusion of nine DURAVYU patients with substantial vision loss characterized by the company as unrelated to wet AMD. The result places extraordinary importance on LUCIA, the identically designed second Phase 3 trial expected to report during the fourth quarter of 2026, because EyePoint, Inc. still hopes to pursue a New Drug Application during the first half of 2027 if the broader clinical package is supportive.

The market response shows how sharply investor expectations have changed. EyePoint, Inc. shares were trading around $4.51 at approximately 2:38 p.m. Eastern Time, down about 69.4% from the previous close, after falling as low as $3.52 during the session. The decline reduced the company’s market capitalization to roughly $389 million, compared with approximately $180 million of cash, cash equivalents and marketable securities reported at June 30. That balance gives EyePoint, Inc. time to reach LUCIA and its diabetic macular edema readouts, but the valuation now indicates that investors are assigning substantially less probability to DURAVYU becoming the large wet AMD commercial franchise previously anticipated.

LUGANO’s primary endpoint miss matters more to investors than DURAVYU’s favorable secondary results

LUGANO and LUCIA are identical randomized, double-masked and active-controlled Phase 3 trials comparing DURAVYU 2.7 milligrams dosed every six months with on-label aflibercept. More than 900 patients were enrolled across the two studies, and the primary endpoint evaluates non-inferiority in average change in best corrected visual acuity at weeks 52 and 56. LUGANO did not meet that endpoint in the full dataset, meaning the first pivotal study did not provide the prospectively defined efficacy result EyePoint, Inc. intended to use within its regulatory package.

EyePoint, Inc. attributed the miss in part to an asymmetric group of nine among 211 DURAVYU-treated patients who lost at least 15 letters for reasons the company determined were unrelated to wet AMD or inadequate disease control. No patients in the aflibercept arm experienced comparable unrelated vision loss. When those nine patients were excluded in an ad hoc analysis, DURAVYU met the non-inferiority criterion with a nominal p-value of 0.0096.

That analysis may provide a clinically plausible explanation, but it cannot carry the same evidentiary weight as the original prespecified analysis. Post-hoc exclusions occur after investigators have seen the data and therefore face greater scrutiny from regulators and investors. For EyePoint, Inc., the critical question is no longer whether management can construct an analysis showing non-inferiority, but whether the United States Food and Drug Administration ultimately considers the full Phase 3 package sufficiently consistent and reliable to support review.

LUCIA now provides an unusually clean way to test the company’s explanation. Because the second pivotal trial uses essentially the same design, dose, comparator and primary endpoint, a positive LUCIA result would support the argument that LUGANO was distorted by an atypical imbalance rather than inadequate DURAVYU activity. Another primary-endpoint miss would be considerably more difficult to reconcile with the original regulatory thesis and could force EyePoint, Inc. to reconsider its planned 2027 filing strategy.

A 42% reduction in injection burden keeps DURAVYU commercially interesting if LUCIA succeeds

The market selloff does not mean LUGANO produced a clinically empty dataset. DURAVYU achieved a 42% reduction in treatment burden compared with on-label aflibercept, meeting superiority on that secondary endpoint with a nominal p-value below 0.0001. EyePoint, Inc. said that translated into approximately two fewer injections per patient through week 56.

Durability was similarly encouraging. Seventy-six percent of DURAVYU patients required no supplemental aflibercept through week 32 and 94% required no more than one supplement. At week 56, 54% remained entirely supplement free and 79% had received either zero or one supplemental injection. A prespecified analysis of supplement-free patients showed non-inferiority in visual acuity compared with supplement-free aflibercept patients, with a nominal p-value of 0.0035.

Retinal anatomy also remained close to control. Central subfield thickness differed by only four microns between the DURAVYU and aflibercept groups at week 56, while the DURAVYU patients who remained supplement free showed a three-micron difference. EyePoint, Inc. also reported no meaningful differences in cataracts, elevated intraocular pressure or intraocular inflammation and no observed cases of retinal vasculitis, insert migration or severe intraocular inflammation.

These characteristics explain why DURAVYU could still have significant commercial value if LUCIA provides stronger pivotal evidence. Wet AMD is a lifelong condition requiring repeated treatment, and EyePoint, Inc. is attempting to compete primarily on durability rather than simply producing another anti-VEGF therapy with similar dosing requirements. DURAVYU combines the tyrosine kinase inhibitor vorolanib with a bioerodible sustained-delivery technology designed to release drug for at least six months after a standard intravitreal administration.

The potential commercial proposition is therefore straightforward. If physicians can preserve vision and retinal anatomy while reducing the number of injections and clinic visits, a six-month treatment interval could address a meaningful burden for patients and retinal practices. LUGANO demonstrated much of that product profile, but commercial differentiation cannot compensate for an approval problem if the pivotal evidence does not satisfy regulators.

EyePoint’s $180m cash runway buys time for LUCIA but the company is spending heavily on Phase 3

EyePoint, Inc. reported $180 million in cash, cash equivalents and marketable securities at June 30, down from $223 million at the end of March. Management previously expected those resources to support operations into the fourth quarter of 2027, extending beyond both wet AMD Phase 3 readouts and through important milestones in the diabetic macular edema program.

That runway becomes more valuable after the LUGANO setback because EyePoint, Inc. does not need to raise capital immediately before obtaining the LUCIA result. At the same time, the balance sheet is being consumed rapidly. Second-quarter operating expenses reached $97.9 million compared with $67.6 million a year earlier, while research and development expenses alone totaled $83.6 million. The company recorded a quarterly net loss of $94.5 million.

Much of the spending reflects the scale of the DURAVYU strategy. EyePoint, Inc. is simultaneously running two pivotal wet AMD trials, two Phase 3 diabetic macular edema trials and commercial manufacturing expansion intended to prepare for potential launch. COMO and CAPRI, the diabetic macular edema studies, completed enrollment of more than 480 patients in five months and are expected to report topline results during the fourth quarter of 2027.

Those additional trials preserve strategic optionality if the wet AMD pathway becomes more difficult. Positive diabetic macular edema results could still validate DURAVYU in another major retinal market, but they arrive more than a year after LUCIA and require continued spending before EyePoint, Inc. knows whether the second indication succeeds. The company therefore has enough liquidity to reach several critical data points, but today’s valuation collapse makes future capital much more expensive if additional financing eventually becomes necessary.

The roughly $389 million current market capitalization is only a little more than twice the June-end cash and investment balance. That comparison should not be read as evidence that EyePoint, Inc. is automatically undervalued because the company is burning substantial capital and its lead asset now carries greater regulatory risk. It does show how aggressively investors have discounted the value of the clinical pipeline following one failed prespecified Phase 3 endpoint.

LUCIA now represents a potential valuation reset in either direction for EyePoint shareholders

Before August 17, LUCIA was primarily viewed as the second pivotal confirmation needed to complete DURAVYU’s wet AMD registration package. After the LUGANO result, it carries a much heavier burden. A clean primary-endpoint success could partially rehabilitate confidence in the program, particularly if visual outcomes, treatment-burden reductions and anatomical results resemble the positive portions of LUGANO.

Such an outcome would not erase the first trial’s failure, but it could give EyePoint, Inc. a stronger basis for discussing how the totality of the evidence should be interpreted with the FDA. Management continues to target a possible NDA submission during the first half of 2027 pending LUCIA, although that timetable remains an objective rather than a confirmed regulatory path. Additional LUGANO subgroup analyses are expected at retina conferences beginning with the Retina Society Annual Scientific Meeting in September.

A second miss would create a fundamentally different scenario. Two failed primary endpoints would make the favorable treatment-burden and supplement-free results much harder to translate into an approval strategy, regardless of the clinical convenience DURAVYU might offer. It would also put greater pressure on the diabetic macular edema program to justify the hundreds of millions of dollars already invested in development and manufacturing infrastructure.

The nearly 70% share-price decline indicates that investors have moved rapidly toward pricing that downside risk before LUCIA reports. EyePoint, Inc. still owns a therapy that demonstrated long dosing intervals, strong retinal anatomy and an apparently manageable safety profile in LUGANO, but the stock market is emphasizing the part of the dataset that matters most for regulatory predictability: the prospectively defined primary endpoint failed.

The fourth-quarter LUCIA result could therefore become one of the more binary biotechnology catalysts of late 2026. Success would support the argument that LUGANO contained an unusual imbalance and potentially reopen the route toward a 2027 FDA filing. Failure would raise considerably larger questions about whether DURAVYU can justify its late-stage development program in wet AMD at all.

Key takeaways on what the DURAVYU Phase 3 miss means for EyePoint, Inc.

• DURAVYU failed the prespecified LUGANO Phase 3 primary endpoint of non-inferiority to on-label aflibercept in the full wet AMD dataset.
• EyePoint, Inc. said nine of 211 DURAVYU patients experienced substantial vision loss unrelated to wet AMD, while no comparable cases occurred in the control arm.
• Excluding those nine patients in an ad hoc analysis produced non-inferiority with a nominal p-value of 0.0096, but the original primary analysis remains negative.
• DURAVYU reduced treatment burden by 42% and resulted in approximately two fewer injections per patient through week 56.
• Fifty-four percent of DURAVYU patients remained free of supplemental injections through week 56, while 79% required zero or one supplement.
• LUCIA, the identically designed second wet AMD Phase 3 study, is expected to report during the fourth quarter of 2026 and has become the central near-term catalyst.
• EyePoint, Inc. still anticipates a potential NDA submission during the first half of 2027, subject to the LUCIA results and the regulatory interpretation of the overall package.
• The company held $180 million in cash and investments at June 30 and expects its runway to extend into the fourth quarter of 2027.
• EyePoint, Inc. shares were down about 69.4% at roughly $4.51 during August 17 trading, reducing the company’s market capitalization to approximately $389 million.
• The stock collapse reflects sharply negative investor sentiment toward DURAVYU’s regulatory probability despite clinically favorable secondary outcomes, leaving LUCIA positioned for a potentially large valuation reset in either direction.